Cue Biopharma, Inc.

Contributing Author

Recent Articles by Cue Biopharma, Inc.

1 hour	Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments CUE -14.05% GlobeNewswire
May-07	Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CUE +5.15% GlobeNewswire
Apr-30	Cue Biopharma Announces $30 Million Private Placement CUE +106.38% CUE +13.38% GlobeNewswire
Apr-30	Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody CUE +106.38% CUE +13.38% GlobeNewswire
Apr-30	Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company CUE +106.38% CUE +13.38% GlobeNewswire
Apr-22	Cue Biopharma Announces 1-for-30 Reverse Stock Split CUE -13.42% GlobeNewswire
Apr-15	Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 CUE +65.37% GlobeNewswire
Apr-08	Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement CUE +45.48% GlobeNewswire
Mar-27	Cue Biopharma Announces CEO Transition CUE -5.60% CUE GlobeNewswire
Mar-26	Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 CUE -5.03% GlobeNewswire
Mar-16	Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights CUE -12.84% CUE +9.80% GlobeNewswire
Mar-09	Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 CUE GlobeNewswire
Feb-17	Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases CUE -5.06% GlobeNewswire
Feb-12	Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer CUE -6.75% GlobeNewswire
Dec-19	Cue Biopharma Announces Pricing of $10 Million Public Offering CUE -21.58% GlobeNewswire
Dec-18	Cue Biopharma Announces Proposed Public Offering CUE -14.50% GlobeNewswire
Nov-12	Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights CUE -7.19% CUE GlobeNewswire
Nov-06	Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors CUE GlobeNewswire
Sep-29	Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates CUE GlobeNewswire
Aug-21	Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference CUE GlobeNewswire
Aug-13	Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme CUE GlobeNewswire
Aug-12	Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights CUE GlobeNewswire
Jul-16	Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer CUE +22.29% GlobeNewswire
Jul-01	Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies CUE GlobeNewswire
Jun-24	Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease CUE +10.43% CUE +8.67% GlobeNewswire
May-12	Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights CUE GlobeNewswire
May-08	Cue Biopharma to Host Virtual Investor Event on May 15, 2025 CUE GlobeNewswire
May-05	Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference CUE GlobeNewswire

Cue Biopharma, Inc.

Recent Articles by Cue Biopharma, Inc.

Upgrade your Finviz experience